| | 1626387-80-1 Basic information More.. |
| Product Name: | AZD 3759 | | Synonyms: | AZD 3759;(2R)-2,4-Dimethyl-1-piperazinecarboxylic acid 4-[(3-chloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl ester;HY-18750;azd3579;1-Piperazinecarboxylic acid, 2,4-dimethyl-, 4-[(3-chloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl ester, (2R)-;1-PIPERAZINECARBOXYLIC ACID, 2,4-DIMETHYL-, 4-[(3-CHLORO-2-FLUOROPHENYL)AMINO]-7-METHOXY-6-QUINAZOLINYL ESTER;4-((3-Chloro-2-fluorophenyl)amino)-7-methoxyquinazolin-6-yl (2R)-2,4-dimethylpiperazine-1-carb;(R)-4-((3-chloro-2-fluorophenyl)amino)-7-methoxyquinazolin-6-yl 2,4-dimethylpiperazine-1-carboxylate | | CAS: | 1626387-80-1 | | MF: | C22H23ClFN5O3 | | MW: | 459.9 | | EINECS: | 1592732-453-0 | | Mol File: | 1626387-80-1.mol |  |
Use
AZD3759 is an EGFP inhibitor (Epidermal growth factor receptor tyrosine kinase inhibitor) with blood brain barrier (BBB) penetration. It has the potential for the treatment of non-small cell lung cancer (NSCLC), with brain metastases (BM) and leptomengingeal metastases (LM) since this type of cancer often contain a lot of activating mutations of the epidermal growth factor receptor (EGFR). It has excellent capability of penetrating the blood brain barrier to reach the central nervous system.
- AZD3759
-
- 2026-09-03
- CAS:1626387-80-1
- Min. Order: 1g
- Purity: More Than 99%
- Supply Ability: 100kg/Month
- AZD3759.
-
- 2026-09-03
- CAS:1626387-80-1
- Min. Order: 1g
- Purity: More Than 99%
- Supply Ability: 100kg/Month
- Zorifertinib
-
- $37.00
- 2026-07-27
- CAS:1626387-80-1
- Purity: 98.29%
- Supply Ability: 10g
|
|
1626387-80-1
Recommend Suppliers |
|